Active Ingredient: Peginterferon alpha-2a
Peginterferon alpha-2a is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAgnegative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
180 - 180 ug
From 180 To 180 ug once every 7 day(s) for 336 day(s)
The recommended dosage and duration of peginterferon alpha-2a for both HBeAg-positive and HBeAg-negative CHB is 180 micrograms once weekly for 48 weeks.
Peginterferon alpha-2a is administered subcutaneously in the abdomen or thigh. Exposure to peginterferon alpha-2a was decreased in studies following administration of peginterferon alpha-2a in the arm.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
